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Ezetimibe stimulates faecal neutral sterol (FNS) excretion in mice, which cannot be explained by
cholesterol absorption inhibition alone. We investigated whether these effects are mediated via
the sterol exporter ATP binding cassette transporter G8 (abcg8). Ezetimibe increased FNS excretion
2.7-fold in WT mice and 1.5-fold in abcg8/ mice, without affecting biliary cholesterol secretion.
Daily FNS excretion exceeded the sum of dietary cholesterol intake and biliary secretion by about
60%. Ezetimibe enhanced this ‘extra’ FNS excretion by 3.5-fold and 1.5-fold in wildtype (WT) and
abcg8/ mice, respectively. Ezetimibe stimulates fecal sterol excretion of non-biliary and non-die-
tary origin, probably through stimulation of trans-intestinal cholesterol excretion. We show that
this effect depends on intact abcg8 function.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Whole-body cholesterol homeostasis is regulated by a complex
interaction of de novo synthesis, intestinal absorption, biliary
clearance and faecal excretion. The precise mechanisms by which
cholesterol is absorbed from and secreted back into the intestinal
lumen for faecal removal are not fully understood, although the
ATP binding cassette (ABC) half-transporters G5 and G8 and the
Niemann-Pick C1 Like 1 (NPC1L1) protein have been shown to play
a crucial role [1,2]. Abcg5 and ATP binding cassette transporter G8
(abcg8) are located at the apical membrane of the small intestine
and at the canalicular membrane in the liver, where they function
as heterodimeric efﬂux transporters, promoting excretion of cho-
lesterol and non-cholesterol sterols; from enterocytes into the
intestinal lumen and from hepatocytes into the bile [3,4]. NPC1L1
is a transporter protein, which mediates cholesterol and plantchemical Societies. Published by E
orter G8; BW, body weight;
1L1, Niemann-Pick C1 Like 1;
lta; RCT, reverse cholesterol
; WT, wildtypesterol absorption from intestinal micelles into the enterocyte [5].
It was believed to reside strictly at the apical intestinal membrane,
although it is becoming clear that NPC1L1 might have additional
intracellular locations and functions [6–8]. NPC1L1 is the molecu-
lar target of ezetimibe [5], which is used as a cholesterol lowering
agent, although its exact function and targets are not completely
elucidated [9,10].
The inhibitory effect of ezetimibe on intestinal sterol absorption
has been well established in mice [2] and humans [11]. However,
ezetimibe was recently also shown to enhance reverse cholesterol
transport (RCT) from macrophages in mice, via yet unidentiﬁed
mechanisms [12]. Interestingly, when assessing cholesterol bal-
ance in ezetimibe-treated mice, it appears that this enhancement
cannot be attributed to cholesterol absorption inhibition or in-
creased biliary cholesterol secretion alone. In fact, it has been sug-
gested that ezetimibe might stimulate faecal neutral sterol (FNS)
excretion through a novel intestinal pathway for RCT [13]. Since
the abcg5/g8 heterodimer has been shown to mediate this trans-
intestinal cholesterol excretion (TICE) route [14], we hypothesized
that the effects of ezetimibe on FNS excretion might depend on
abcg5/g8 function. Therefore, we investigated the effects of eze-
timibe treatment on cholesterol balance in wildtype mice (WT)
and in mice deﬁcient for abcg8 (abcg8/).lsevier B.V. All rights reserved.
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Fig. 1. Faecal neutral sterol excretion. Faecal neutral sterol excretion in abcg8/
and WT mice after an AM-II diet or AM-II + 0.5% cholate diet with and without
10 mg/kg/day ezetimibe in lmol/day/100 g BW. Differences between treatment
groups were analysed by the unpaired Student’s t test. * Signiﬁcantly different from
the control diet (P = 0.007). Since faeces were pooled per group in the cholate
experiment, statistically signiﬁcant differences in FNS could not be assessed.
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2.1. Animals and procedures
Abcg8/ C57BL/6J mice were generated as previously de-
scribed [15]. In the current study, male abcg8/ mice and their
WT littermates, two to six months of age, were housed in cages
in a temperature-controlled room with 12 h light cycling. Mice
were fed ad libitum a chow diet containing 0.018% cholesterol
(AM-II, Hope-Farms, Wageningen, The Netherlands) with or with-
out 10 mg/kg/day of ezetimibe for a period of 21 days. On day 20,
mice were placed in a new cage for 24 h faeces collection. On day
21, mice were anesthetized with Hypnorm (fentanyl/ﬂuanisone;
1 ml/kg) and diazepam (10 mg/kg), after which bile was collected
from the gallbladders by bile duct cannulation for 15 min. Here-
after the mice were sacriﬁced. Livers were excised and weighed.
Each experimental group consisted of ﬁve mice. Two or three mice
were housed per cage in order to mimic their normal situation. In
order to enhance intestinal cholesterol absorption, experiments
were repeated with a 0.5% (w/w) cholate-enriched AM-II diet in
the same mouse strains.
In theWTmice, we also measured fractional cholesterol absorp-
tion rates, by means of an adapted plasma dual isotope method, as
previously described [14]. In brief, at the end of each period, mice
received an intravenous dose of 0.3 mg (0.76 lmol) cholesterol-D7
dissolved in Intralipid (20%, Fresenius Kabi, Den Bosch, the Nether-
lands), together with an oral dose of 0.6 mg (1.54 lmol) choles-
terol-D5 dissolved in medium chain triglyceride oil. Blood spots
were collected from the tail on ﬁlter paper before administration
of labeled cholesterol and at 24 h intervals for 4 days. Experimental
procedures were approved by the Ethical Committee for Animal
Experiments of the Academic Medical Centers in Amsterdam and
Groningen, The Netherlands.
2.2. Analytical procedures
Faeces were pooled per group, weighed and homogenized. Neu-
tral sterols and bile salts were analysed according to Arca et al. [16]
and Setchell et al. [17]. Biliary cholesterol, phospholipids and bile
acids were determined as described by Frijters et al. [18].
Plasma enrichments of cholesterol-D7 and -D5 were measured
by means of GC–MS, according to Neese et al. [19], after cholesterol
extraction from blood spots with 1 ml of 95% ethanol/acetone (1:1,
v/v). Fractional cholesterol absorption was calculated by division of
the plasma ratio of oral cholesterol-D5 and intravenous choles-
terol-D7 at T = 72 h, by the administered D5/D7 ratio at T = 0.
2.3. Statistical analyses
Data were analysed by SPSS software version 15.0.1 for Win-
dows (SPSS Inc, Chicago, USA). Differences between treatment
groups and differences between genotype groups respectively,
were analysed by unpaired Student’s t-tests. A P value less than
0.05 was considered statistically signiﬁcant.cholate + ezecholateAM-II + ezeAM-II
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Fig. 2. Biliary cholesterol secretion. Biliary cholesterol secretion in abcg8/ and
WT mice after an AM-II diet or AM-II + 0.5% cholate diet with and without 10 mg/
kg/day ezetimibe in lmol/day/100 g BW. * Signiﬁcantly different from abcg8/
mice (P < 0.05).3. Results
3.1. Faecal sterols
In abcg8/ mice, ezetimibe induced a 1.5-fold increase in FNS
excretion when compared to the control AM-II diet (15.1 ±
1.9 lmol/day/100 g body weight (BW) versus 10.1 ± 1.6 lmol/
day/100 g BW, P = 0.053). This ezetimibe-induced increase was
approximately 2.7-fold in WT mice (22.9 ± 2.2 lmol/100 g BW
compared to 8.4 ± 2.7 lmol/100 g BW, P = 0.007, Fig. 1).When the experiment was repeated in the presence of cholate,
more pronounced increases in FNS excretion were observed in the
ezetimibe-treated mice (Fig. 1). In WT mice, ezetimibe induced a
mean 20-fold increase in FNS excretion when compared to the con-
trol diet (270.7 lmol/day/100 g BW compared to 13.3 lmol/day/
100 g BW). This ezetimibe-induced increase was strongly attenu-
ated in the absence of abcg8, as the increase in FNS excretion
was only eightfold in abcg8/mice (32.9 lmol/day/100 g BW ver-
sus 3.9 lmol/100 g BW). Since faeces were pooled per group in the
latter experiment, statistical signiﬁcance could not be evaluated.
To account for possible miscalculations, the measurements were
repeated in different sets of animals, yielding similar results. The
data presented in Fig. 1 are the average of these two measure-
ments. Finally, there were no differences in faecal bile acids be-
tween groups (data not shown).
3.2. Biliary parameters
Ezetimibe treatment did not signiﬁcantly affect biliary
cholesterol levels in abcg8/ (1.3 ± 0.3 lmol/day/100 g BW versus
1.0 ± 0.3 lmol/day/100 g BW, P = 0.176) nor in WT mice (1.5 ±
0.3 lmol/day/100 g BW versus 1.9 ± 0.8 lmol/day/100 g BW,
P = 0.328, Fig. 2). Mice fed with a cholate-enriched diet showed
strongly induced biliary cholesterol secretion. However, on this
Table 1
Cholesterol balance.
Dietary cholesterol intake
lmol/day/100 g BW
Biliary cholesterol secretion
lmol/day/100 g BW
Fecal neutral sterol excretion
lmol/day/100 g BW
Abcg8/ AM-II diet 8.3 ± 0.6 1.0 ± 0.3 10.1 ± 1.6
Abcg8/ AM-II + ezetimibe 6.8 ± 0.5 1.3 ± 0.3 15.1 ± 1.9
C57Bl6 AM-II diet 6.4 ± 0.3 1.9 ± 0.8 8.4 ± 2.7
C57Bl6 AM-II + ezetimibe 7.9 ± 1.0 1.5 ± 0.3 22.9 ± 2.2
Abcg8/ AM-II + cholate 7.3 ± 1.7 5.6 ± 0.9 3.9a
Abcg8/ AM-II + cholate + ezetimibe 7.1 ± 0.5 6.6 ± 2.1 32.9a
C57Bl6 AM-II + cholate 7.5 ± 1.4 31.3 ± 18.0 13.3a
C57Bl6 AM-II + cholate + ezetimibe 7.8 ± 1.9 40.2 ± 8.8 270.7a
Cholesterol input and output in abcg8/ and wildtype mice (lmol/day/100 g BW).
a Since faeces were pooled per group, standard deviations could not be evaluated.
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cholesterol levels in both abcg8/ mice (6.6 ± 2.1 lmol/day/
100 g BW versus 5.6 ± 0.9 lmol/day/100 g BW, P = 0.343, Fig. 2)
and in WT mice (40.2 ± 8.8 lmol/day/100 g BW versus
31.3 ± 18.0 lmol/day/100 g BW, P = 0.346, Fig. 2). No differences
in biliary phospholipid and bile salt excretion and liver weight
were found between groups. This also applied when the cholate-
enriched diet was used (data not shown).
3.3. Cholesterol balance
Table 1 displays cholesterol input and output data of abcg8/
and WT mice on the AM-II diet and the AM-II cholate-enriched
diet, with and without ezetimibe. WT mice on an AM-II diet con-
sumed 6.4 ± 0.3 lmol/100 g BW of cholesterol per day and ex-
creted 8.4 ± 2.7 lmol/day/100 g BW of cholesterol and its neutral
sterol metabolites in the faeces. Since daily biliary cholesterol
secretion was 1.9 ± 0.8 lmol/day/100 g BW, the amount of choles-
terol entering the intestinal lumen each day was approximately
8.3 lmol/day/100 g BW. We found a fractional cholesterol absorp-
tion rate of 48 ± 11% (n = 5) in these mice. Based on these numbers,
the expected FNS loss would be 4.3 lmol/day/100 g BW instead of
the observed 8.4 lmol/100 g BW. Hence, approximately 4.1 lmol/
100 g BW of FNS per day appears to be unaccounted for. According
to the same input–output analysis for the abcg8/ mice, the
amount of FNS which is not derived from either dietary intake or
biliary secretion is approximately 5.3 lmol/100 BW per day. More-
over, when the cholesterol balance calculation is repeated for the
ezetimibe-treated mice, the amount of ‘extra’ FNS increased up
to 14.7 lmol/day/100 g BW for the WT mice and to 8.1 lmol/
day/100 g BW for the abcg8/ mice, based on a fractional choles-
terol absorption of 13 ± 4% (n = 5) in ezetimibe-treated WTmice, as
measured by the plasma dual isotope method. This means that
treatment with ezetimibe elicits a 3.5-fold increase of ‘extra’ FNS
excretion in WT mice, as compared to a 1.5-fold increase in
abcg8/ mice.
For the experiment with the cholate-enriched diet, the ezetim-
ibe-induced stimulation of this ‘extra’ FNS excretion was 6.7-fold
for the abcg8/mice and 20.0-fold for theWTmice, assuming that
cholesterol absorption doubled with cholate feeding [20].
4. Discussion
This study shows that in mice, ezetimibe stimulates FNS excre-
tion in an abcg8-dependent manner, without stimulation of hepa-
tobiliary cholesterol secretion. This implies that ezetimibe
stimulates faecal excretion of non-dietary and non-biliary sterols,
mediated by the intestinal abcg8 transporter.
The observed increases in FNS excretion are in line with
previous reports of ezetimibe treatment in various mice models[21–23]. Initially, on a background AM-II diet, we observed an eze-
timibe-induced 2.7-fold increase in FNS excretion in WT mice,
whereas FNS excretion was merely 1.5-fold increased in abcg8/
mice. In order to increase the potential role of abcg8 in this process,
we repeated our measurements with an AM-II diet enriched with
0.5% cholate. Cholate feeding is known to increase cholesterol
absorption [24] and hepatic abcg5/g8 expression in mice [20,21].
Interestingly, upon ezetimibe treatment, we found a striking 20-
fold increase in FNS excretion in WTmice, compared to a sevenfold
increase in abcg8/ mice. This strongly supports that abcg8 is in-
volved in the ezetimibe-induced stimulation of FNS excretion.
The ezetimibe-induced increase in FNS excretion was not due to
enhanced biliary cholesterol secretion, nor to differences in dietary
cholesterol intake (Table 1). Therefore, these results imply that
ezetimibe stimulates faecal excretion of sterols, which do not orig-
inate either from diet or bile. This ﬁnding is in line with several
murine studies, demonstrating increased FNS loss without con-
comitant changes in biliary sterol excretion, supporting the pres-
ence of a non-biliary route for faecal sterol excretion [25–28].
Moreover, recent perfusion studies of small intestine segments in
mice show that enterocytes can secrete cholesterol directly into
the intestinal lumen throughout the entire length of the small
intestine [29]. TICE is considered to be an liver X receptor (LXR)-/
PPAR-d-dependent pathway of RCT from the periphery for excre-
tion into the faeces [14,23,30,31]. Although no distinct effect of
abcg8-deletion on direct intestinal cholesterol secretion was ob-
served in the in situ perfusion studies [29], recent data in mice
lacking abcg5/g8 convincingly show that this transporter is indeed
involved in this alternative RCT pathway [14,31].
Since we found the ezetimibe-induced increase in faecal sterol
loss to be abcg8-dependent, our ﬁnding might be explained in
the light of direct intestinal cholesterol secretion. Interference of
ezetimibe with RCT is supported by a recent report showing a six-
fold increase in RCT from labelled peripheral tissue macrophages in
mice treated with 0.005% ezetimibe [12]. This was conﬁrmed by
another recent study which showed that ezetimibe promotes fae-
cal excretion of macrophage and HDL-derived cholesterol without
any effect on HDL cholesterol kinetics in C57BL6/J mice [32]. Of
note, the increase in RCT was only 2.5-fold in the latter report,
probably due to methodological differences. Unfortunately, neither
of these studies evaluated the effects of ezetimibe on biliary
cholesterol secretion, nor the possible inﬂuence of the abcg5/g8
transporter on these ﬁndings. However, our data may be in line
with a very recent report which examined cholesterol homeostasis
in mice lacking abcg5/g8, NPC1L1 and both abcg5/g8 and NPC1L1
(triple knockout, TKO) [13]. In this study, NPC1L1/ mice dis-
played an additional 15.5 lmol/day/BW increase in FNS excretion
as compared with TKO. Since the only difference between the
two mouse strains was a non-functional abcg5/g8 transporter in
TKO mice, the authors hypothesized that this additional FNS
3628 L. Jakulj et al. / FEBS Letters 584 (2010) 3625–3628excretion must be attributable to the g5/g8-mediated hepatobilia-
ry and perhaps intestinal secretion of cholesterol. Unfortunately,
the hepatobiliary cholesterol ﬂux was not measured in that study.
However, the current cholesterol balance study implies that abcg8-
mediated intestinal, rather than hepatobiliary cholesterol secretion
underlies this additional FNS excretion.
The molecular mechanism by which ezetimibe stimulates activ-
ity of abcg5/g8 is unclear at present. The cholesterol absorption
inhibitor has no effect on mRNA expression of the partners in the
abcg5/g8 heterodimer. Interestingly, the similar excessive increase
in FNS that has been observed in the NPC1L1/abcg5/g8 TKO mice
[13] suggests that the effect is not due to the cholesterol absorp-
tion inhibitor itself, but relates to the activity of NPC1L1. We spec-
ulate that the absence of NPC1L1 disturbs normal intracellular
vesicle trafﬁcking leading to an increased transport of cholesterol
to the apical membrane of the enterocytes where abcg5/g8 may
mediate efﬂux.
Finally, it is not likely that differences in cholesterol absorption
inhibition could explain the observed differences in stimulation of
FNS loss, since ezetimibe has been shown to reduce cholesterol
absorption equally in abcg5g8/ and WT mice [21]. Although we
did not measure cholesterol absorption in abcg8/ mice, expres-
sion levels of NPC1L1 were shown to be similar in both mouse
strains [13,31] consistent with previous identical fractional choles-
terol absorption rates [3,30], as well as acute intestinal uptake
rates of cholesterol [24]. Finally, fractional cholesterol absorption
did not differ in the abovementioned NPC1L1/abcg5g8 TKO mice,
which is comparable to the situation of ezetimibe treatment in
abcg5/g8/ and WT mice, respectively [13].
In conclusion, we report that ezetimibe promotes FNS excretion,
without affecting hepatobiliary cholesterol secretion. This effect
depends strongly, but not entirely on the presence of abcg5/g8,
suggesting that ezetimibe stimulates TICE, mediated by abcg5/g8.
Through direct assessment of whole body cholesterol balance we
substantiate suggestions by others [13,32]. However, the molecu-
lar mechanism underlying our observation is unclear and warrants
further investigation.
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